Alan A Musso - Net Worth and Insider Trading

Alan A Musso Net Worth

The estimated net worth of Alan A Musso is at least $406 dollars as of 2024-04-27. Alan A Musso is the SVP, CFO & Treasurer of Catalyst Biosciences Inc and owns about 27 shares of Catalyst Biosciences Inc (CBIO) stock worth over $207. Alan A Musso is also the CFO and Treasurer of Bellicum Pharmaceuticals Inc and owns about 2,655 shares of Bellicum Pharmaceuticals Inc (BLCM) stock worth over $198. Details can be seen in Alan A Musso's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Alan A Musso has not made any transactions after 2018-05-25 and currently still holds the listed stock(s).

Transaction Summary of Alan A Musso

Alan A Musso Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Alan A Musso owns 4 companies in total, including Bellicum Pharmaceuticals Inc (BLCM) , Catalyst Biosciences Inc (CBIO) , and Fulcrum Therapeutics Inc (FULC) among others .

Click here to see the complete history of Alan A Musso’s form 4 insider trades.

Insider Ownership Summary of Alan A Musso

Ticker	Comapny	Transaction Date	Type of Owner
BLCM	Bellicum Pharmaceuticals Inc	2018-05-25	CFO and Treasurer
CBIO	Catalyst Biosciences Inc	2011-06-07	VP & CFO & Treasurer & Secretary
FULC	Fulcrum Therapeutics Inc	2023-08-07	Chief Financial Officer
ALRN	Aileron Therapeutics Inc	2023-10-31	director

Alan A Musso Latest Holdings Summary

Alan A Musso currently owns a total of 2 stocks. Among these stocks, Alan A Musso owns 27 shares of Catalyst Biosciences Inc (CBIO) as of June 7, 2011, with a value of $207 and a weighting of 51.06%. Alan A Musso also owns 2,655 shares of Bellicum Pharmaceuticals Inc (BLCM) as of May 25, 2018, with a value of $198 and a weighting of 48.94%.

Latest Holdings of Alan A Musso

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CBIO	Catalyst Biosciences Inc	2011-06-07	27	7.67	207
BLCM	Bellicum Pharmaceuticals Inc	2018-05-25	2,655	0.07	198

Holding Weightings of Alan A Musso

Alan A Musso Form 4 Trading Tracker

According to the SEC Form 4 filings, Alan A Musso has made a total of 0 transactions in Catalyst Biosciences Inc (CBIO) over the past 5 years. The most-recent trade in Catalyst Biosciences Inc is the sale of 294 shares on June 7, 2011, which brought Alan A Musso around $673,075.

According to the SEC Form 4 filings, Alan A Musso has made a total of 0 transactions in Bellicum Pharmaceuticals Inc (BLCM) over the past 5 years. The most-recent trade in Bellicum Pharmaceuticals Inc is the sale of 621 shares on May 25, 2018, which brought Alan A Musso around $49,462.

Insider Trading History of Alan A Musso

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Alan A Musso Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Alan A Musso Ownership Network

Ownership Network List of Alan A Musso

No Data

Ownership Network Relation of Alan A Musso

Alan A Musso Owned Company Details

What does Bellicum Pharmaceuticals Inc do?

Who are the key executives at Bellicum Pharmaceuticals Inc?

Alan A Musso is the CFO and Treasurer of Bellicum Pharmaceuticals Inc. Other key executives at Bellicum Pharmaceuticals Inc include Chief Development Officer Charity Scripture , Principal Accounting Officer Charles S. Grass , and director & President and CEO Richard A. Fair .

Bellicum Pharmaceuticals Inc (BLCM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Bellicum Pharmaceuticals Inc (BLCM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Bellicum Pharmaceuticals Inc (BLCM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Bellicum Pharmaceuticals Inc (BLCM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bellicum Pharmaceuticals Inc Insider Transactions

No Available Data

What does Catalyst Biosciences Inc do?

Who are the key executives at Catalyst Biosciences Inc?

Alan A Musso is the VP & CFO & Treasurer & Secretary of Catalyst Biosciences Inc. Other key executives at Catalyst Biosciences Inc include director & Chief Executive Officer Charles C Wu , director & President Songjiang Ma , and Chief Operating Officer Weiguo Ye .

Catalyst Biosciences Inc (CBIO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Catalyst Biosciences Inc (CBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Catalyst Biosciences Inc (CBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Catalyst Biosciences Inc (CBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Catalyst Biosciences Inc Insider Transactions

No Available Data

What does Fulcrum Therapeutics Inc do?

Who are the key executives at Fulcrum Therapeutics Inc?

Alan A Musso is the Chief Financial Officer of Fulcrum Therapeutics Inc. Other key executives at Fulcrum Therapeutics Inc include Controller Greg Tourangeau , director & See Remarks Alex Sapir , and 10 percent owner Ra Capital Healthcare Fund Lp .

Fulcrum Therapeutics Inc (FULC) Insider Trades Summary

Over the past 18 months, Alan A Musso made no insider transaction in Fulcrum Therapeutics Inc (FULC). Other recent insider transactions involving Fulcrum Therapeutics Inc (FULC) include a net purchase of 4,609,704 shares made by Ra Capital Healthcare Fund Lp , a net sale of 5,094 shares made by Greg Tourangeau , and a net purchase of 43,360 shares made by Alex Sapir .

In summary, during the past 3 months, insiders sold 4,884 shares of Fulcrum Therapeutics Inc (FULC) in total and bought 43,360 shares, with a net purchase of 38,476 shares. During the past 18 months, 11,860 shares of Fulcrum Therapeutics Inc (FULC) were sold and 4,653,064 shares were bought by its insiders, resulting in a net purchase of 4,641,204 shares.

Fulcrum Therapeutics Inc (FULC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fulcrum Therapeutics Inc Insider Transactions

No Available Data

What does Aileron Therapeutics Inc do?

Who are the key executives at Aileron Therapeutics Inc?

Alan A Musso is the director of Aileron Therapeutics Inc. Other key executives at Aileron Therapeutics Inc include See Remarks James Brian Windsor , See Remarks Susan L. Drexler , and 10 percent owner Muneer A Satter .

Aileron Therapeutics Inc (ALRN) Insider Trades Summary

Over the past 18 months, Alan A Musso made no insider transaction in Aileron Therapeutics Inc (ALRN). Other recent insider transactions involving Aileron Therapeutics Inc (ALRN) include a net purchase of 5,301 shares made by James Brian Windsor ,

In summary, during the past 3 months, insiders sold 0 shares of Aileron Therapeutics Inc (ALRN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aileron Therapeutics Inc (ALRN) were sold and 5,301 shares were bought by its insiders, resulting in a net purchase of 5,301 shares.

Aileron Therapeutics Inc (ALRN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aileron Therapeutics Inc Insider Transactions

No Available Data

Alan A Musso Mailing Address

Above is the net worth, insider trading, and ownership report for Alan A Musso. You might contact Alan A Musso via mailing address: Fulcrum Therapeutics, Inc., 26 Landsdowne Street, Cambridge Ma 02139.

Discussions on Alan A Musso

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.